Table 3 Baseline characteristics of the validation cohort

Age (years)

64.89 ± 5.36

68.06 ± 12.39

0.317

Blood eosinophil count (cellsx10⁶/L)

226.66 ± 136.18

280 ± 378

0.738

CRP (mg/L)

9.77 ± 10.28

75.86 ± 102.10

0.049

Urinary protein to creatinine ratio (g/mol)

23.55 ± 19.34

30.34 ± 19.46

0.226

Urine leukocyte count (cells/µL)

16.17 ± 10.98

49.35 ± 65.10

0.226

Hypertension (% patients)

66.7

42.4

0.405

Leucocyturia (%patients)

66.7

81.8

0.245

Hematuria (% patients)

16.7

9.1

0.52

Treatment with ICI (% patients)

100

100

0.99

Treatment with platinum derivatives (% patients)

100

42.4

< 0.001

Urine erytrocyte count (cells/µL)

2.83 ± 3.25

10.67 ± 40.41

0.641

sCreatinine (µmol/L)

180 ± 58.79

231.13 ± 103.22

0.251

Previous CKD (% patients)

16.6

6.1

0.522